NanoViricides (NNVC) Stock Price, News & Analysis

Company Overview

NanoViricides, Inc. (NYSE:NNVC) is a clinical-stage biotechnology company focused on developing antiviral therapies based on its proprietary nanoviricide platform. The company’s approach uses specially designed polymeric nanostructures intended to mimic cellular receptors, bind to virus particles, and interfere with their ability to infect cells.

NanoViricides has developed drug candidates targeting a range of viral diseases, including respiratory infections, shingles and other herpesvirus-related conditions. Its pipeline has included NV-387, an investigational broad-spectrum antiviral candidate, and NV-HHV-1, a topical candidate being developed for shingles and related herpesvirus infections. The company’s candidates remain investigational and are not approved for commercial sale.

Founded in 2005, NanoViricides is headquartered in Shelton, Connecticut. The company conducts its research and development activities primarily in the United States. Anil R. Diwan, Ph.D., is the company’s co-founder, president and chief executive officer.

Key Stats

• Today's Range: $1.49 to $1.78
• 50-Day Range: $1.02 to $1.77
• 52-Week Range: $0.85 to $2.23
• Volume: 1.68 million shs
• Average Volume: 537,441 shs
• Market Capitalization: $43.14 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Buy

NanoViricides Stock Analysis - MarketRank™

NanoViricides scored higher than 42% of companies evaluated by MarketBeat, and ranked 615th out of 895 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

NanoViricides has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

NanoViricides has a consensus price target of $6.00, representing about 255.0% upside from its current price of $1.69.

Amount of Analyst Coverage

NanoViricides has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of NanoViricides is -2.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NanoViricides is -2.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NanoViricides has a P/B Ratio of 2.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for NNVC.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NanoViricides does not currently pay a dividend.

Dividend Growth

NanoViricides does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.10

News Sentiment

NanoViricides has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for NanoViricides this week, compared to 1 article on an average week.

Search Interest

6 people have searched for NNVC on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

11 people have added NanoViricides to their MarketBeat watchlist in the last 30 days. This is an increase of 175% compared to the previous 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NanoViricides insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.60% of the stock of NanoViricides is held by insiders.

Percentage Held by Institutions

10.30% of the stock of NanoViricides is held by institutions.

Company Calendar

• Last Earnings: 9/27/2024
• Today: 9/21/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:NNVC
• CIK: 1379006
• Web: www.nanoviricides.com
• Phone: (203) 668-5580
• Fax: 203-859-5095
• Employees: 7
• Year Founded: 2005

Price Target and Rating

• Average Price Target for NanoViricides: $6.00
• High Price Target: $6.00
• Low Price Target: $6.00
• Potential Upside/Downside: +255.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.43)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.29 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -87.90%
• Return on Assets: -78.69%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.44
• Quick Ratio: 2.47

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.66 per share
• Price / Book: 2.56

Miscellaneous

• Outstanding Shares: 25,527,000
• Free Float: 14,922,000
• Market Cap: $43.14 million
• Optionable: Optionable
• Beta: 1.66